Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.

Authors :: Mazagatos C
Mendioroz J
Rumayor MB
Gallardo García V
Álvarez Río V
Cebollada Gracia AD
Batalla Rebollo N
Barranco Boada MI
Pérez-Martínez O
Lameiras Azevedo AS
López González-Coviella N
Castrillejo D
Fernández Ibáñez A
Giménez Duran J
Ramírez Córcoles C
Ramos Marín V
Larrauri A
Monge S
Source :: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 May; Vol. 18 (5), pp. e13294.
Publication Year :: 2024
Abstract: Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.<br />Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.<br />Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.<br /> (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)

Subjects :: Humans
Spain epidemiology
Infant
Incidence
Female
Male
Respiratory Syncytial Virus, Human
Sentinel Surveillance
Infant, Newborn
Antibodies, Monoclonal, Humanized therapeutic use
Respiratory Syncytial Virus Infections epidemiology
Respiratory Syncytial Virus Infections drug therapy
Hospitalization statistics & numerical data
Antiviral Agents therapeutic use

Full Text Access

Tools